Clinical Trials Browser

Phase 1/2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × ruxolitinib × Clear all

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01914484 2020-11-02

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia